Dr. O'Neill serves as a member of the Executive Board and provides consulting on many aspects of vision science with a specific focus on drug development and nonclinical considerations for regulatory submissions. Dr. O’Neill has 30 years of biotechnology and pharmaceutical development experience. Currently, he is a Co-Founder, Chief Executive Officer and Board Chair at MCAL Therapeutics, Inc. that is developing a novel evaporative dry eye therapy. From 2004 to 2023 Dr.
Dr. Crosson serves as a member of the Executive Board and provides consulting on many aspects of vision science with a specific focus on pharmacology and animal models of elevated intraocular pressure, retinal degenerations and macular edema. Dr. Crosson is a Professor in the Department of Ophthalmology at the Medical University of South Carolina (MUSC). He is also Director of the Ola B. Williams Glaucoma Therapeutic Development Center and Senior Associate Dean for Research at MUSC. His research interests include ischemia, neovascularization, and neuroprotection.